EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

An artificial intelligence (AI)-based approach to clinical trial recruitment: The impact of Viz RECRUIT on enrollment in the EMBOLISE trial

Ameer E Hassan iD, Saisree Ravi iD, Sohum Desai iD, Hamzah M Saei, Ermias Mckennon iD, Wondwossen G Tekle iD

Interventional Neuroradiology · 2025-12 · 31 (6) · 739-744

DOI: 10.1177/15910199231184604 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Interventional Neuroradiology, online erschienen am 22.06.2023. Verfasst von Ameer E Hassan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of Texas Rio Grande Valley School of Medicine, Harlingen, TX, USA. Hauptthemen laut MEDLINE: Artificial Intelligence, Embolization, Therapeutic, Patient Selection. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

EMBOLISE (NCT 04402632) is an ongoing randomized controlled trial investigating the safety and efficacy of middle meningeal artery embolization for the treatment of subacute or chronic subdural hematoma (SDH). Viz RECRUIT SDH is an artificial intelligence (AI)-based software platform that can automatically detect SDH in noncontrast computed tomography (NCHCT) images and report the volume, maximum thickness, and midline shift. We hypothesized that the mobile recruitment platform would aid enrollment and coordinate communication and image sharing among the entire research team. Materials and methods Patient enrollment in EMBOLISE prior to and after implementation of Viz RECRUIT SDH at a large comprehensive stroke center was compared along with the performance of the software platform. The EMBOLISE trial was activated on May 5, 2021, and Viz RECRUIT SDH was activated on October 6, 2021. The pre-AI cohort consisted of all patients from EMBOLISE to AI activation (153 days), and the post-AI cohort consisted of all patients from AI activation until August 18, 2022 (316 days). All alerts for suspected SDH candidates were manually reviewed to determine the positive predictive value (PPV) of the algorithm.

Results

Prior to AI-software implementation, there were 5 patients enrolled (0.99 patients/month) and one screen failure. After the implementation of the software, enrollment increased by 36% to 1.35 patients/month (14 total enrolled), and there were no screen failures. Over the entire post-AI period, a total of 6244 NCHCTs were processed by the system with 207 total SDH detections (3% prevalence). 35% of all alerts for suspected SDH were viewed within 10 min, and 50% were viewed within an hour. The PPV of the algorithm was 81.4 (CI [75.3, 86.7]).

Conclusion

The implementation of an AI-based software for the automatic screening of SDH patients increased the enrollment rate in the EMBOLISE trial, and the software performed well in a real-world, clinical trial setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Artificial IntelligenceEmbolization, TherapeuticPatient SelectionAgedFemaleHumansMaleMiddle AgedRandomized Controlled Trials as TopicSoftwareTomography, X-Ray Computed

Stichwörter der Autor:innen

AIMMA embolizationartificial intelligenceclinical trialsubduraltechnology

Autor:innen und Institutionen

  • Department of Neurology, University of Texas Rio Grande Valley School of Medicine, Harlingen, TX, USA.
  • Department of Neuroscience, Valley Baptist Medical Center, Harlingen, TX, USA.

ORCID-Profile: Ameer E Hassan, Saisree Ravi, Sohum Desai, Ermias Mckennon, Wondwossen G Tekle

Zitieren

APA

Hassan, A. E., Ravi, S., Desai, S., Saei, H. M., Mckennon, E., & Tekle, W. G. (2025). An artificial intelligence (AI)-based approach to clinical trial recruitment: The impact of Viz RECRUIT on enrollment in the EMBOLISE trial. Interventional Neuroradiology, 31(6), 739-744. https://doi.org/10.1177/15910199231184604

Vancouver

Hassan AE, Ravi S, Desai S, Saei HM, Mckennon E, Tekle WG. An artificial intelligence (AI)-based approach to clinical trial recruitment: The impact of Viz RECRUIT on enrollment in the EMBOLISE trial. Interventional Neuroradiology. 2025;31(6):739-744. doi:10.1177/15910199231184604

BibTeX
@article{Hassan2025,
  author = {Hassan, Ameer E and Ravi, Saisree and Desai, Sohum and Saei, Hamzah M and Mckennon, Ermias and Tekle, Wondwossen G},
  title = {An artificial intelligence (AI)-based approach to clinical trial recruitment: The impact of Viz RECRUIT on enrollment in the EMBOLISE trial},
  journal = {Interventional Neuroradiology},
  year = {2025},
  volume = {31},
  number = {6},
  pages = {739--744},
  doi = {10.1177/15910199231184604}
}
Kostenlos starten →